Journal of Neurology

, Volume 259, Issue 11, pp 2429–2433 | Cite as

Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria

  • Dimitri RenardEmail author
  • Giovanni Castelnovo
  • Anne Wacongne
  • Anne Le Floch
  • Eric Thouvenot
  • Julie Mas
  • Audrey Gabelle
  • Pierre Labauge
  • Sylvain Lehmann
Original Communication


According to the modified Boston criteria, cerebral amyloid angiopathy (CAA) can present with lobar hematoma (LH) or superficial siderosis (SS). Recently, decreased CSF β-amyloid peptide 40 and 42 (Aβ40; Aβ42) and increased total and phosphorylated tau (t-tau; p-tau) concentrations have been described in CAA presenting with LH. Our aim was to analyze CSF biomarkers as a diagnostic tool for CAA according to the modified Boston criteria. We prospectively included patients with possible or probable CAA according to the modified Boston criteria. CSF was analyzed for t-tau, p-tau, Aβ42, and Aβ40. Data were compared with AD patients (n = 42) and controls (n = 14). Thirteen CAA patients were included, nine presenting with LH and four with SS. T-tau and p-tau levels in CAA were higher than controls, but lower than in AD. Differences in t-tau and p-tau levels between CAA versus controls and AD were all significant apart of the CAA p-tau levels comparison with controls. Aβ42 levels in CAA were significantly lower than in controls, and slightly higher than in AD, though non-significantly. Aβ40 levels in CAA were non-significantly lower than in controls, and significantly lower than in AD. Combining the findings of our study and the earlier report, we confirm that patients with suspected CAA have significantly different values for t-tau, Aβ42, Aβ42/t-tau, and Aβ40. Especially Aβ40 levels seem to be of clinical interest to differentiate CAA from AD. CSF biomarkers have to be analyzed in a larger number of CAA patients, and compared to patients with other disorders causing LH or SS.


Cerebral amyloid angiopathy Lobar hematoma Superficial siderosis Aβ40 Aβ42 t-tau p-tau CSF biomarkers 



A.G. has received funding for travel expenses for AD conferences from Novartis.

Conflicts of interest

There are no other conflicts of interest to report for any of the authors.


  1. 1.
    Knudsen KA, Rosand J, Karluk D, Greenberg SM (2001) Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56:537–539PubMedCrossRefGoogle Scholar
  2. 2.
    Verbeek MM, Kremer BP, Rikkert MO et al (2009) Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 66:245–249PubMedCrossRefGoogle Scholar
  3. 3.
    Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer’ disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234PubMedCrossRefGoogle Scholar
  4. 4.
    Vemuri P, Wiste HJ, Weigand SD et al (2009) Alzheimer disease neuroimaging initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73:287–293PubMedCrossRefGoogle Scholar
  5. 5.
    Goos JD, Teunissen CE, Veerhuis R et al. (2011) Microbleeds relate to altered amyloid-beta metabolism in Alzheimer’s disease. Neurobiol Aging 33:1011.e1–1011.e9Google Scholar
  6. 6.
    Linn J, Halpin A, Demearel P et al (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 74:1346–1350PubMedCrossRefGoogle Scholar
  7. 7.
    van Rooden S, van der Grond J, van den Boom R et al (2009) Descriptive analysis of the Boston criteria applied to a Dutch-type cerebral amyloid angiopathy population. Stroke 40:3022–3027PubMedCrossRefGoogle Scholar
  8. 8.
    Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856–861PubMedCrossRefGoogle Scholar
  9. 9.
    Conover WJ (1999) Practical nonparametric statistics, 3rd edn. Wiley, New YorkGoogle Scholar
  10. 10.
    Bibl M, Mollenhauer B, Esselmann H et al (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187PubMedCrossRefGoogle Scholar
  11. 11.
    Pijnenburg YA, Schoonenboom SN, Mehta PD et al (2007) Decreased cerebrospinal fluid amyloid beta (1–40) levels in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 78:735–737PubMedCrossRefGoogle Scholar
  12. 12.
    Gabelle A, Roche S, Gény C et al (2011) Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimer Dis 26:553–563Google Scholar
  13. 13.
    Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746PubMedCrossRefGoogle Scholar
  14. 14.
    Hernandez-Guillamon M, Delgado P, Penalba A et al. (2012) Plasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis 10:320–323Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Dimitri Renard
    • 1
    Email author
  • Giovanni Castelnovo
    • 1
  • Anne Wacongne
    • 1
  • Anne Le Floch
    • 1
  • Eric Thouvenot
    • 2
  • Julie Mas
    • 1
  • Audrey Gabelle
    • 3
    • 4
  • Pierre Labauge
    • 1
  • Sylvain Lehmann
    • 4
  1. 1.Department of NeurologyCHU Nîmes, Hôpital CaremeauNîmes Cedex 9France
  2. 2.Department of NeurologyCHU Nîmes, Hôpital Caremeau, Université Montpellier INîmes Cedex 9France
  3. 3.Centre Mémoire de Ressources et de Recherche MontpellierCHU Montpellier, Hôpital Gui de Chauliac, Université Montpellier IMontpellier Cedex 5France
  4. 4.Biochimie-Protéomique Clinique, IRB, CCBHM, Inserm U1040CHU Montpellier, Hôpital St-Eloi, Université Montpellier IMontpellier Cedex 5France

Personalised recommendations